JUAN ANGEL: Open Payments
NPI 1811475213 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,042 in 99 payments from 17 companies in 2025. Trend: 2023 $1,366 · 2024 $1,972 · 2025 $3,042
Food & beverage: $2,943Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $532 |
| Regeneron Healthcare Solutions, Inc. | 15 | $494 |
| GENZYME CORPORATION | 11 | $344 |
| GlaxoSmithKline, LLC. | 18 | $318 |
| Optinose US, Inc. | 2 | $277 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $208 |
| Genentech USA, Inc. | 5 | $186 |
| Genentech, Inc. | 1 | $139 |
| Novartis Pharmaceuticals Corporation | 5 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $139 |
Products named: DUPIXENT, TEZSPIRE, Xolair, Xhance, NUCALA, NEFFY, AIRSUPRA, CUVITRU.
Industry payments across FL — which companies pay providers there.
